Non-vitamin K antagonist oral anticoagulants: Considerations on once- vs. twice-daily regimens and their potential impact on medication adherence

Europace

Volumn 17, Issue 4, 2015, Pages 514-523

  Vrijens, Bernard ^a,b   Heidbuchel, Hein ^c  

^a MWV Healthcare   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c HASSELT UNIVERSITY   (Belgium)

Author keywords

Anticoagulation; Atrial fibrillation; Compliance; Dosing regimens; Medication adherence; Monitoring; New oral anticoagulants; Stroke

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MEASUREMENT ACCURACY; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RELIABILITY; REVIEW; SIMULATION; TREATMENT REFUSAL; DOSE RESPONSE; DRUG ADMINISTRATION; MEDICATION COMPLIANCE; ORAL DRUG ADMINISTRATION; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; THROMBOEMBOLISM; VITAMIN K;

EID: 84924362080     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu311     Document Type: Review

References (40)

1. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997;95:1085-90.
2. Lutfey KE, Wishner WJ. Beyond "compliance" is "adherence". Improving the prospect of diabetes care. Diabetes Care 1999;22:635-9.
3. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al. A new taxonomy for describing and defining adherence to medications. Brit J Clin Pharmacol 2012;73:691-705.
4. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
5. PatelMR, MahaffeyKW, Garg J, Pan G, Singer DE, HackeWet al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981-92.
7. Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007;167:229-35.
8. Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 2005;45:461-7.
9. Laliberte F, Cloutier M, NelsonWW, Coleman CI, Pilon D, Olson WH et al. Realworld comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-25.
10. Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs 2013;73:545-62.
11. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012;52:275-301.
12. Glintborg B, Hillestrom PR, Olsen LH, Dalhoff KP, Poulsen HE. Are patients reliable when self-reporting medication use? Validation of structured drug interviews and home visits by drug analysis and prescription data in acutely hospitalized patients. J Clin Pharmacol 2007;47:1440-9.
13. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968-77.
14. Smith SR,Wahed AS, Kelley SS, Conjeevaram HS, Robuck PR, FriedMWet al. Assessing the validity of self-reported medication adherence in hepatitisC treatment. Ann Pharmacother 2007;41:1116-23.
15. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther 1989;46:163-8.
16. Rubio A, Cox C,Weintraub M. Prediction of diltiazemplasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet 1992;22: 238-46.
17. STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370:1702-11.
18. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990;150:1509-10.
19. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990;150:1377-8.
20. Kass MA, Gordon M, MeltzerDW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol 1986;101:524-30.
21. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials 2008;9:238-46.
22. Vrijens B, Urquhart J, White D. Electronically monitored dosing histories can be used to develop a medication-taking habit and manage patient adherence. Expert Rev Clin Pharmacol 2014;7:633-44.
23. Arnet I, Walter PN, Hersberger KE. Polymedication Electronic Monitoring System (POEMS)-a new technology for measuring adherence. Front Pharmacol 2013;4:26.
24. Chan AH, Reddel HK, Apter A, Eakin M, Riekert K, Foster JM. Adherence monitoring and e-health: how clinicians and researchers can use technology to promote inhaler adherence for asthma. J Allergy Clin Immunol Pract 2013;1:446-54.
25. Lugaresi A. RebiSmart (version 1.5) device for multiple sclerosis treatment delivery and adherence. Expert Opin Drug Deliv 2013;10:273-83.
26. Belknap R,Weis S, Brookens A, Au-Yeung KY, MoonG, DiCarlo L et al. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PloS One 2013;8:e53373.
27. Eisenberger U, Wuthrich RP, Bock A, Ambuhl P, Steiger J, Intondi A et al. Medication adherence assessment: high accuracy of the new Ingestible Sensor System in kidney transplants. Transplantation 2013;96:245-50.
28. Laliberte F, NelsonWW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-90.
29. Comte L, Vrijens B, Tousset E, Gerard P, Urquhart J. Estimation of the comparative therapeutic superiority ofQDand BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn 2007;34: 549-58.
30. Blaschke TF. Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes. Curr Opin HIV AIDS 2008;3:603-7.
31. Vrijens B, Claeys MJ, Legrand V, Vandendriessche E, Van deWerf F. Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Brit J Clin Pharmacol 2014; 77:746-55.
32. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held Cet al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes.NEngl J Med 2009; 361:1045-57.
33. Heidbuchel H, Verhamme P, Alings M, Antz M, HackeW, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51.
34. Heidbuchel H, all authors of the EPG, Verhamme P, Alings M, AntzM, HackeWet al. Authors' response: from monitoring to vigilance about patient adherence to new oral anticoagulants. Europace 2014;16:149-50.
35. Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, CammAJ et al. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmesas away to structure daily practice. Eur Heart J 2013;34:2725-30.
36. Verhamme P, Heidbuchel H. Organizing patient-centred anticoagulant therapy. Acta Cardiol 2013;68:413-5.
37. Heidbuchel H. Telemonitoring of implantable cardiac devices: hurdles towards personalised medicine. Heart 2011;97:931-9.
38. Schmidt S, Sheikzadeh S, Beil B, Patten M, Stettin J. Acceptance of telemonitoring to enhance medication compliance in patients with chronic heart failure. Telemed J E-health 2008;14:426-33.
39. Hendriks JM, de WitR, Crijns HJ, Vrijhoef HJ, Prins MH, PistersRet al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J 2012;33:2692-9.
40. Hendriks JM, Vrijhoef HJ, Crijns HJ, Brunner-La Rocca HP. The effect of a nurse-led integrated chronic care approach on quality of life in patients with atrial fibrillation. Europace 2014;16:491-9.